Cargando…

Theranostics in Oncology—Thriving, Now More than Ever

Tracing its roots back to the 1940s, theranostics in nuclear oncology has proved successful mainly due to the beneficial effects of image-guided therapeutic concepts for patients afflicted with a variety of different cancers. The majority of these treatments are not only characterized by substantial...

Descripción completa

Detalles Bibliográficos
Autores principales: Werner, Rudolf A., Higuchi, Takahiro, Pomper, Martin G., Rowe, Steven P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8146294/
https://www.ncbi.nlm.nih.gov/pubmed/33946670
http://dx.doi.org/10.3390/diagnostics11050805
_version_ 1783697365560983552
author Werner, Rudolf A.
Higuchi, Takahiro
Pomper, Martin G.
Rowe, Steven P.
author_facet Werner, Rudolf A.
Higuchi, Takahiro
Pomper, Martin G.
Rowe, Steven P.
author_sort Werner, Rudolf A.
collection PubMed
description Tracing its roots back to the 1940s, theranostics in nuclear oncology has proved successful mainly due to the beneficial effects of image-guided therapeutic concepts for patients afflicted with a variety of different cancers. The majority of these treatments are not only characterized by substantial prolongation of progression-free and overall survival, but are also generally safe, rendering theranostic agents as an attractive treatment option in various clinical scenarios in oncology. In this Special Issue Novel Theranostic Agents, nine original articles from around the globe provide further evidence on the use of the theranostic concept for neuroendocrine neoplasm (NEN), prostate cancer (PC), meningioma, and neuroblastoma. The investigated diagnostic and therapeutic radiotracers target not only established structures, such as somatostatin receptor, prostate-specific membrane antigen or norepinephrine transporter, but also recently emerging targets such as the C-X-C motif chemokine receptor 4. Moreover, the presented original articles also combine the concept of theranostics with in-depth read-out techniques such as radiomics or novel reconstruction algorithms on pretherapeutic scans, e.g., for outcome prediction. Even 80 years after its initial clinical introduction, theranostics in oncology continues to thrive, now more than ever.
format Online
Article
Text
id pubmed-8146294
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-81462942021-05-26 Theranostics in Oncology—Thriving, Now More than Ever Werner, Rudolf A. Higuchi, Takahiro Pomper, Martin G. Rowe, Steven P. Diagnostics (Basel) Editorial Tracing its roots back to the 1940s, theranostics in nuclear oncology has proved successful mainly due to the beneficial effects of image-guided therapeutic concepts for patients afflicted with a variety of different cancers. The majority of these treatments are not only characterized by substantial prolongation of progression-free and overall survival, but are also generally safe, rendering theranostic agents as an attractive treatment option in various clinical scenarios in oncology. In this Special Issue Novel Theranostic Agents, nine original articles from around the globe provide further evidence on the use of the theranostic concept for neuroendocrine neoplasm (NEN), prostate cancer (PC), meningioma, and neuroblastoma. The investigated diagnostic and therapeutic radiotracers target not only established structures, such as somatostatin receptor, prostate-specific membrane antigen or norepinephrine transporter, but also recently emerging targets such as the C-X-C motif chemokine receptor 4. Moreover, the presented original articles also combine the concept of theranostics with in-depth read-out techniques such as radiomics or novel reconstruction algorithms on pretherapeutic scans, e.g., for outcome prediction. Even 80 years after its initial clinical introduction, theranostics in oncology continues to thrive, now more than ever. MDPI 2021-04-29 /pmc/articles/PMC8146294/ /pubmed/33946670 http://dx.doi.org/10.3390/diagnostics11050805 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Editorial
Werner, Rudolf A.
Higuchi, Takahiro
Pomper, Martin G.
Rowe, Steven P.
Theranostics in Oncology—Thriving, Now More than Ever
title Theranostics in Oncology—Thriving, Now More than Ever
title_full Theranostics in Oncology—Thriving, Now More than Ever
title_fullStr Theranostics in Oncology—Thriving, Now More than Ever
title_full_unstemmed Theranostics in Oncology—Thriving, Now More than Ever
title_short Theranostics in Oncology—Thriving, Now More than Ever
title_sort theranostics in oncology—thriving, now more than ever
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8146294/
https://www.ncbi.nlm.nih.gov/pubmed/33946670
http://dx.doi.org/10.3390/diagnostics11050805
work_keys_str_mv AT wernerrudolfa theranosticsinoncologythrivingnowmorethanever
AT higuchitakahiro theranosticsinoncologythrivingnowmorethanever
AT pompermarting theranosticsinoncologythrivingnowmorethanever
AT rowestevenp theranosticsinoncologythrivingnowmorethanever